Laham Y, Ringelstein-Harlev S, Kurnik D, Fineman R, Yehudai-Ofir D, Bonstein L, Setter-Marco N, Braun E, Ghersin I, Zuckerman T, Beyar-Katz O. High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. haematol [Internet]. 2020Sep.10 [cited 2025Feb.1];. Available from: https://haematologica.org/article/view/11898